03206nas a2200253 4500008004100000245007500041210006900116260001500185300001000200490000700210520243400217653003102651653001302682653001102695653001302706653001302719653001802732100002502750700002802775700003302803700002802836700002902864856005902893 2022 eng d00aResearch Policy of the Institutional Review Board in Pharmacy Practice0 aResearch Policy of the Institutional Review Board in Pharmacy Pr cApril 2022 a15-190 v113 a

Objectives: This study aims to declare the Research policy of the Institutional Review Board at pharmaceutical care services as a new initiative in Saudi Arabia. Methods: This article is a narrative review of pharmacy research. Litterateur researched specific research policies and procedures in pharmacy practice using a variety of databases, including PubMed, Medline, and Google Scholar. The period covered for the search is from the 1960s to October 2021. The terms used are in the English language and encompasses narrative reviews, systemic reviews, meta-analyses, and guidelines. The search term includes all hospital and community pharmacy-related services. Besides, there are national and international guidelines for conducting general research in hospital practice. The pharmacy research committee was formed and comprised numerous expert members, including clinical pharmacists, pharmacists specializing in drug information, and clinical research specialists. A member drafted the policy’s guidelines, which were then reviewed and corrected by another member. The research specialist made the third revision. The subject emphasizes the research policy of the Institutional Review Board in pharmacy practice. Results: The Institutional Review Board’s definition and functions were examined. The policies and procedures have been established. In pharmacy research, there were three distinct categories of actions. That includes Exempted Research, in which no risks to patients are involved. For example, a review of a new program or service, a cost analysis, therapeutic guidelines, review articles, a systematic review, a meta-analysis, or a cross-sectional study. Expedited Research posed little risk to patients. The Complete revision Research has a high risk of adverse effects on patients, such as clinical trials. Conclusion: The Institutional Review Board for research policies in pharmaceutical care services is a new initiative within pharmacy departments’ research and development efforts. The Institutional Review Board for research policies in pharmaceutical care services may enhance pharmacy research and the benefits of investments in pharmacy practice within a healthcare organization. Besides, prevent any adverse events associated with the investigational drug and improve patient clinical outcomes.

10aInstitutional Review Board10aPharmacy10aPolicy10aPractice10aResearch10aSaudi Arabia.1 aAlomi, Yousef, Ahmed1 aAl-Najjar, Amal, Hassan1 aAbushomi, Hamidah, Qasim Ali1 aAlmadany, Maha, Hussein1 aAlmasoudi, Abeer, Hussin uhttps://ijphs.org/article/2022/11/1/105530ijpcs2022114